Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1817 results
March 2020
-
StatementNovartis coronavirus update (supply chain, response measures, EFPIA R&D call)
-
Novartis Social Business Careers: improving health in lower income countries
This is the story of how three Novartis colleagues took a career decision to improve health in lower income countries.
-
Featured NewsInternational Women’s Day 2020
To celebrate International Women’s Day we explore how an inclusive environment that values unique and curious minds helps everyone be inspired to innovate every day.
-
Advancing medicine through collaboration
In Wendi Yajnik’s quest to find new technologies that could transform medicine, relationships are priority No. 1.
-
Clinical trial comes together in weeks to address coronavirus
Researchers race to put hydroxychloroquine to the test in a large study.
-
Media ReleaseInternational research partnership and EDCTP to invest €44m in next-generation antimalarials to combat drug-resistant malaria in AfricaEDCTP grants the PAMAfrica research consortium €21.9 million over a 5 year period; MMV, Novartis and other partners will provide an additional €22 million. The PAMAfrica consortium brings…
-
Key ReleaseSandoz Resolves Generic Drug Antitrust Investigation in the U.S.Princeton, New Jersey, March 2, 2020 – Sandoz Inc. has reached a resolution with the U.S. Department of Justice (DOJ) Antitrust Division concerning the Department’s more than three-year-long…
February 2020
-
Key ReleaseNovartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General MeetingShareholders approve 23rd consecutive dividend increase to CHF 2.95 (+4%) per share for 2019; representing a 3.5%1 yield and approximately 54% payout of free cash flow Shareholders confirm Dr.…
-
Key ReleaseLes actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration à l’Assemblée générale annuelleLes actionnaires approuvent la 23e augmentation consécutive du dividende qui passe à CHF 2.95 (+4%) par action pour l’année 2019, soit un rendement de 3,5%1 et une distribution du free cash-flow…
-
Parental Leave at Novartis: Alfred’s story
At Novartis, we celebrate life and recognize moments that matter. Alfred Ambatlle shares his experience of parental leave and becoming a father of twins.
-
Media ReleaseNovartis and DNDi to collaborate on the development of a new oral drug to treat visceral leishmaniasisLXE408 is a first-in-class compound, discovered at Novartis with financial support from the Wellcome Trust Novartis is responsible for completing Phase I clinical trials and has committed to…
-
Shaping the future of sickle cell disease
Collaborations are driving advances in sickle cell disease research, bringing new hope to patients.
Pagination
- ‹ Previous page
- 1
- …
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- …
- 152
- › Next page